KindlyMD, Inc. (NASDAQ:NAKA) Stock Has Average Price Target of $20.00 According to Analysts

Key Points

• Analysts have a consensus “Hold” rating on KindlyMD, with three buys, one hold and one sell among five analysts. The average 12-month price target is $20.00, although recent targets range from $13 to $17.
• KindlyMD reported a quarterly loss of $6.65 per share on $35.87 million in revenue, alongside a negative 63.45% return on equity and a projected full-year loss of $12.94 per share.
• Insiders have been buying shares, including CEO David Bailey’s purchase of 4,852 shares, while institutional investors including Hunting Hill Global Capital and Yorkville Advisors established new positions. The stock opened at $9.11 and has traded between $3.33 and $47.40 over the past year.

Shares of KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) have earned an average rating of "Hold" from the five analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $20.00.

Several brokerages recently commented on NAKA. B. Riley Financial increased their price objective on shares of KindlyMD from $11.00 to $13.00 and gave the company a "buy" rating in a research report on Tuesday, September 22nd. TD Cowen boosted their target price on shares of KindlyMD from $1.00 to $17.00 and gave the stock a "buy" rating in a research report on Monday, July 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of KindlyMD in a research note on Friday, August 7th.

Insider Buying and Selling at KindlyMD

In related news, CEO David F. Bailey acquired 4,852 shares of the company's stock in a transaction dated Thursday, August 20th. The shares were purchased at an average cost of $6.27 per share, with a total value of $30,422.04. Following the completion of the acquisition, the chief executive officer directly owned 3,185,246 shares of the company's stock, valued at $19,971,492.42. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired 41,904 shares of company stock worth $235,231 over the last 90 days. 24.49% of the stock is owned by insiders.

Institutional Trading of KindlyMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. J. Derek Lewis & Associates Inc. purchased a new stake in KindlyMD during the 4th quarter valued at about $167,000. Hunting Hill Global Capital LLC purchased a new position in shares of KindlyMD in the fourth quarter worth about $4,672,000. Arrington Capital Management LLC acquired a new stake in shares of KindlyMD during the fourth quarter worth about $1,028,000. Waddell & Associates LLC acquired a new stake in shares of KindlyMD during the fourth quarter worth about $201,000. Finally, Yorkville Advisors Global LP acquired a new stake in shares of KindlyMD during the fourth quarter worth about $3,265,000.

KindlyMD Price Performance

Shares of NASDAQ:NAKA opened at $9.11 on Friday. The business's 50-day moving average is $7.02 and its 200 day moving average is $6.72. KindlyMD has a 1 year low of $3.33 and a 1 year high of $47.40. The firm has a market capitalization of $163.07 million, a P/E ratio of -0.25 and a beta of 15.80.

KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%.The business had revenue of $35.87 million during the quarter. On average, analysts expect that KindlyMD will post -12.94 EPS for the current year.

About KindlyMD

KindlyMD, Inc is a healthcare company focused on providing integrated care for patients with complex medical needs, including chronic pain and substance use disorders. Its care model combines primary care, behavioral health services and medication-assisted treatment, with an emphasis on coordinated, patient-centered treatment.

The company has operated clinics in Utah and has also used telehealth and other technology-enabled services to expand access to care. KindlyMD's services are designed to support patients through ongoing treatment and recovery rather than addressing individual medical issues in isolation.

KindlyMD became a publicly traded company through a business combination involving Nakamoto Holdings, with its common stock trading on the Nasdaq under the symbol NAKA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.